Tom 14, Nr 1 (2019)
Artykuły
Opublikowany online: 2019-04-08

dostęp otwarty

Wyświetlenia strony 542
Wyświetlenia/pobrania artykułu 1445
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Stosowanie biwalirudyny u pacjentów z ostrym zespołem wieńcowym poddawanych przezskórnym interwencjom wieńcowym w Polsce: aktualizacja stanowiska ekspertów Asocjacji Interwencji Sercowo-Naczyniowych Polskiego Towarzystwa Kardiologicznego

Łukasz Kołtowski, Jacek Legutko, Krzysztof J. Filipiak, Artur Dziewierz, Stanisław Bartuś, Paweł Buszman, Piotr Buszman, Dariusz Ciećwierz, Maciej Dąbrowski, Sławomir Dobrzycki, Robert Gil, Jarosław Gorący, Marek Grygier, Miłosz Jaguszewski, Janusz Kochman, Jacek Kubica, Wiktor Kuliczkowki, Piotr Lodziński, Andrzej Ochała, Krzysztof Reczuch, Adam Witkowski, Wojciech Wojakowski, Jarosław Wójcik, Dariusz Dudek
Kardiol Inwazyjna 2019;14(1):34-40.

Streszczenie

Brak

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Sanchis-Gomar F, Perez-Quilis C, Leischik R, et al. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016; 4(13): 256.
  2. Wożakowska-Kapłon B, Lesiak M, Ochała A, et al. Bivalirudine use in the acute myocardial infarction in patients undergoing percutaneous coronary interventions: consensus statement of experts from the Cardiovascular Pharmacotherapy Working Group and the Association on Cardiovascular Interventions of the Polish Cardiac Society. Kardiol Pol. 2014; 72(8): 761–765.
  3. Valgimigli M, Frigoli E, Leonardi S, et al. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet. 2018; 392(10150): 835–848.
  4. Shah R, Jovin IS, Chaudhry A, et al. Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention. Catheter Cardiovasc Interv. 2019; 93(2): 241–247.
  5. Anantha-Narayanan M, Anugula D, Gujjula NR, et al. Bivalirudin versus heparin in percutaneous coronary intervention-a systematic review and meta-analysis of randomized trials stratified by adjunctive glycoprotein IIb/IIIa strategy. J Thorac Dis. 2018; 10(6): 3341–3360.
  6. Grajek S, Michalak M, Gwizdała A, et al. Patients treated with bivalirudin are still at higher risk of stent thrombosis: a comprehensive meta-analysis of randomised clinical trials of bivalirudin and heparin for percutaneous coronary interventions. Kardiol Pol. 2018; 76(4): 740–749.
  7. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. ESC Scientific Document Group , ESC Scientific Document Group . 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019; 40(2): 87–165.
  8. Kereiakes D, Yeh R, Massaro J. Stent thrombosis in drug-eluting or bare-metal stents in patients receiving dual antiplatelet therapy. JACC: Cardiovasc Interv. 2015; 8(12): 1552–1562.
  9. Kam PCA, Kaur N, Thong CL. Direct thrombin inhibitors: pharmacology and clinical relevance. Anaesthesia. 2005; 60(6): 565–574.
  10. Alquwaizani M, Buckley L, Adams C, et al. Anticoagulants: a review of the pharmacology, dosing, and complications. Curr Emerg Hosp Med Rep. 2013; 1(2): 83–97.
  11. Cannon CP, Maraganore JM, Loscalzo J, et al. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol. 1993; 71(10): 778–782.
  12. Stratmann G, deSilva AM, Tseng EE, et al. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg. 2004; 98(6): 1635–9, table of contents.
  13. Valgimigli M, Frigoli E, Leonardi S, et al. MATRIX Investigators. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med. 2015; 373(11): 997–1009.
  14. Erlinge D, Koul S, Omerovic E, et al. Bivalirudin versus heparin monotherapy in myocardial infarction. N Engl J Med. 2017; 377(12): 1132–1142.
  15. Eikelboom JW, Connolly SJ, Bosch J. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017; 377 (14): 1319–1330.
  16. Mallifi JR, Lotfi AS. Management of STEMI in patients on NOACs and undergoing primary PCI. Expert analysis ACC website 2015. https://www.acc.org/latest-in-cardiology/articles/2015/.
  17. Witkowski A, Barylski M, Filipiak KJ, et al. Non-vitamin K antagonist oral anticoagulants (NOACs) in the treatment of coronary and peripheral atherosclerosis. Expert Consensus. Kardiol Pol. 2019 [Epub ahead of print].
  18. Wojtasik-Bakalarz J, Kleczyński P, Zasada W, et al. Safety of bivalirudin versus unfractionated heparin in endovascular revascularization of peripheral arteries in short- and long-term follow-up. Advances in Interventional Cardiology. 2019.
  19. Stone GW, Maehara A, Witzenbichler B, et al. INFUSE-AMI Investigators. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. 2012; 307(17): 1817–1826.
  20. Stone GW, Witzenbichler B, Guagliumi G, et al. HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008; 358(21): 2218–2230.
  21. Stone G, McLaurin B, Cox D. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006; 355(21): 2203–2216 –2216.
  22. Steg PG, van 't Hof A, Hamm CW, et al. EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. N Engl J Med. 2013; 369(23): 2207–2217.
  23. Wallentin L, Becker RC, Budaj A, et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11): 1045–1057.
  24. Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357(20): 2001–2015.
  25. Koster A, Faraoni D, Levy JH. Argatroban and bivalirudin for perioperative anticoagulation in cardiac surgery. Anesthesiology. 2018; 128(2): 390–400.
  26. Schwenkglenks M, Toward T, Plent S, et al. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction. Heart. 2012; 98(7): 544–551.
  27. Borg S, Persson U, Allikmets K, et al. Comparative cost-effectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-receptor inhibitor in patients undergoing percutaneous coronary intervention in Sweden: a decision-analytic model. Clin Ther. 2006; 28(11): 1947–1959.